US9434726B2 - Substituted pyrido[3,4-b]pyrazines as Syk inhibitors - Google Patents

Substituted pyrido[3,4-b]pyrazines as Syk inhibitors Download PDF

Info

Publication number
US9434726B2
US9434726B2 US14/124,325 US201214124325A US9434726B2 US 9434726 B2 US9434726 B2 US 9434726B2 US 201214124325 A US201214124325 A US 201214124325A US 9434726 B2 US9434726 B2 US 9434726B2
Authority
US
United States
Prior art keywords
alkyl
optionally substituted
halo
hydrogen
butyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US14/124,325
Other languages
English (en)
Other versions
US20140121200A1 (en
Inventor
Wei-guo Su
Wei Deng
Jianguo Ji
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hutchmed Ltd
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47295336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US9434726(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Assigned to HUTCHISON MEDIPHARMA LIMITED reassignment HUTCHISON MEDIPHARMA LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DENG, WEI, SU, WEI-GUO, JI, JIANGUO
Publication of US20140121200A1 publication Critical patent/US20140121200A1/en
Application granted granted Critical
Publication of US9434726B2 publication Critical patent/US9434726B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • the present invention relates to novel pyridopyrazine compounds, pharmaceutical compositions thereof and methods of use therefore.
  • Spleen Tyrosine Kinase is a member of the Syk family of tyrosine kinases, and is a regulator of early B-cell development as well as mature B-cell activation, signaling, and survival.
  • Syk is a non-receptor tyrosine kinase that plays critical roles in immunoreceptor- and integrin-mediated signaling in a variety of cell types, including B cells, macrophages, monocytes, mast cells, eosinophils, basophils, neutrophils, dendritic cells, T cells, natural killer cells, platelets, and osteoclasts.
  • Immunoreceptors as described herein include classical immunoreceptors and immunoreceptor-like molecules.
  • Classical immunoreceptors include B-cell and T-cell antigen receptors as well as various immunoglobulin receptors (Fc receptors).
  • Immunoreceptor-like molecules are either structurally related to immunoreceptors or participate in similar signal transduction pathways, and are primarily involved in non-adaptive immune functions, including, for example, neutrophil activation, natural killer cell recognition, and osteoclast activity. Integrins are cell surface receptors that play key roles in the control of leukocyte adhesion and activation in both innate and adaptive immunity.
  • Syk is essential for B-cell activation through B-cell receptor (BCR) signaling.
  • BCR B-cell receptor
  • SYK becomes activated upon binding to phosphorylated BCR and thus initiates the early signaling events following BCR activation.
  • B-cell signaling through BCR can lead to a wide range of biological outputs, which in turn depend on the developmental stage of the B-cell. The magnitude and duration of BCR signals must be precisely regulated.
  • Aberrant BCR-mediated signaling can cause disregulated B-cell activation and/or the formation of pathogenic auto-antibodies leading to multiple autoimmune and/or inflammatory diseases.
  • Mice lacking Syk show impaired maturation of B-cells, diminished immunoglobulin production, compromised T-cell-independent immune responses, and marked attenuation of the sustained calcium sign upon BCR stimulation.
  • Protein-based therapeutics such as Rituxan developed to deplete B-cells represent an approach to the treatment of a number of autoimmune and inflammatory diseases.
  • Auto-antibodies and their resulting immune complexes are known to play pathogenic roles in autoimmune disease and/or inflammatory disease.
  • the pathogenic response to these antibodies is dependent on signaling through Fc Receptors, which is, in turn, dependent upon Syk. Because of Syk's role in B-cell activation, as well as FcR dependent signaling, inhibitors of Syk can be useful as inhibitors of B-cell mediated pathogenic activity, including autoantibody production. Therefore, inhibition of Syk enzymatic activity in cells is proposed as a treatment for autoimmune disease through its effects on autoantibody production.
  • Syk also plays a key role in FC ⁇ RI mediated mast cell degranulation and eosinophil activation.
  • Syk binds to the phosphorylated gamma chain of FC ⁇ RI via its SH2 domains and is essential for downstream signaling.
  • Syk deficient mast cells demonstrate defective degranulation, and arachidonic acid and cytokine secretion. This also has been shown for pharmacologic agents that inhibit Syk activity in mast cells.
  • Syk antisense oligonucleotides inhibit antigen-induced infiltration of eosinophils and neutrophils in an animal model of asthma.
  • Syk deficient eosinophils also show impaired activation in response to FC ⁇ RI stimulation. Therefore, small molecule inhibitors of Syk may be useful for treatment of allergy-induced inflammatory diseases including asthma.
  • Syk is also expressed in mast cells and monocytes and has been shown to be important for the function of these cells. For example, Syk deficiency in mice is associated with impaired IgE-mediated mast cell activation, which causes marked diminution of TNF-alpha and other inflammatory cytokine release. Additionally, Syk inhibitors have been shown to inhibit antigen-induced passive cutaneous anaphylaxsis, bronchoconstriction and bronchial edema in rats.
  • the inhibition of Syk activity can be useful for the treatment of allergic disorders, autoimmune diseases, and inflammatory diseases, such as: SLE, rheumatoid arthritis, multiple vasculitides, idiopathic thrombocytopenic purpura (ITP), myasthenia gravis, allergic rhinitis, chronic obstructive pulmonary disease (COPD), adult respiratory distress syndrome (ARDs) and asthma.
  • SLE rheumatoid arthritis
  • multiple vasculitides idiopathic thrombocytopenic purpura
  • IPP idiopathic thrombocytopenic purpura
  • COPD chronic obstructive pulmonary disease
  • ARDs adult respiratory distress syndrome
  • Syk has been reported to play an important role in ligand-independent tonic signaling through the B-cell receptor, known to be an important survival signal in B-cells.
  • inhibition of Syk activity may be useful in treating certain types of cancer, including B-cell lymphoma and leukemia.
  • R 1 is independently chosen from hydrogen, halo, —CN, hydroxyl, optionally substituted C 1 -C 6 alkyl, optionally substituted C 3 -C 6 cycloalkyl, optionally substituted amino, and optionally substituted C 1 -C 6 alkoxy,
  • R 2 is —NR 5 R 6 , —OR 7 , —S(O) n R 8 , —C(O)R 9 , —C(O)OR 7 , —C(O)NR 5 R 6 , —NR 5 C(O)R 9 , —NR 5 S(O) n R 8 , —NR 5 S(O) n NR 10 R 11 , —NR 5 C(O)OR 7 , —NR 5 C(O)NR 10 R 11 , —S(O) n NR 5 R 6 , optionally substituted lower alkyl, optionally substituted alkenyl, and optionally substituted alkynyl;
  • R 3 and R 4 together with the N atom to which they are attached, can form a 4-12 membered mono-cyclic, fused bicyclic or spirocyclic ring optionally containing an additional 1-3 hetero-atoms chosen from N, O and S, which is optionally substituted with one or more groups selected from halo, —NR 5 R 6 , —OR 7 , —S(O) n R 8 , —C(O)R 9 , —C(O)OR 7 , —CN, —C(O)NR 5 R 6 , —NR 5 C(O)R 9 , —NR 5 S(O) n R 8 , —NR 5 S(O) n NR 10 R 11 , —NR 5 C(O)OR 7 , —NR 5 C(O)NR 10 R 11 , —NO 2 , —S(O) n NR 5 R 6 , optionally substituted lower alkyl, optionally substituted cycloalky
  • n 1 or 2
  • R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are independently selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, hydroxyl, cyano, optionally substituted lower alkyl, optionally substituted lower alkoxyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylacyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted amino, and optionally substituted amide, optionally substituted sulfonamide,
  • R 5 and R 6 , R 5 and R 7 , R 5 and R 8 , R 5 and R 9 , and R 5 and R 10 together with the atom(s) to which they are attached can form a ring, which is optionally substituted with one or more groups selected from halo, hydroxyl, cyano, optionally substituted lower alkyl, optionally substituted lower alkoxyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylacyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted amino, and optionally substituted amide, optionally substituted sulfonamide.
  • each optionally substituted group above for which the substituent(s) is (are) not specifically designated can be unsubstituted or independently substituted with, for example, one or more, such as one, two, or three, substituents independently chosen from C 1 -C 4 alkyl, cycloalkyl, aryl, heterocycle, heteroaryl, aryl-C 1 -C 4 alkyl-, heteroaryl-C 1 -C 4 alkyl-, C 1 -C 4 haloalkyl-, —OC 1 -C 4 alkyl, —OC 1 -C 4 alkylphenyl, —C 1 -C 4 alkyl-OH, —C 1 -C 4 alkyl-O—C 1 -C 4 alkyl, —OC 1 -C 4 haloalkyl, halo, —OH, —NH 2 , —C 1 -C 4 alkyl-NH 2 , —N(C 1 -C 4 alkyl,
  • composition comprising at least one compound and/or at least one pharmaceutically acceptable salt thereof described herein and at least one pharmaceutically acceptable carrier.
  • a dash (“-”) that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, —CONH 2 is attached through the carbon atom.
  • alkyl herein refers to a straight or branched hydrocarbon, containing 1-18, preferably 1-12, more preferably 1-6 carbon atoms.
  • alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, and t-butyl.
  • “Lower alkyl” refers to a straight or branched hydrocarbon, containing 1-6, preferably 1-4 carbon atoms.
  • alkoxy is meant a straight or branched alkyl group containing 1-18, preferably 1-12, more preferably 1-6 carbon atoms attached through an oxygen bridge such as, for example, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, pentoxy, 2-pentyloxy, isopentoxy, neopentoxy, hexoxy, 2-hexoxy, 3-hexoxy, 3-methylpentoxy, and the like.
  • Alkoxy groups will usually have from 1 to 6 carbon atoms attached through the oxygen bridge.
  • “Lower alkoxy” refers to a straight or branched alkoxy, wherein the alkyl portion contains 1-6, preferably 1-4 carbon atoms.
  • alkenyl herein refers to a straight or branched hydrocarbon, containing one or more C ⁇ C double bonds and 2-10, preferably 2-6 carbon atoms.
  • alkenyl groups include, but are not limited to, vinyl, 2-propenyl, and 2
  • alkynyl herein refers to a straight or branched hydrocarbon, containing one or more C ⁇ O triple bonds and 2-10, preferably 2-6 carbon atoms.
  • alkynyl groups include, but are not limited to, ethynyl, 2-propynyl, and 2
  • cycloalkyl refers to saturated and partially unsaturated cyclic hydrocarbon groups having 3 to 12, preferably 3 to 8 carbon atoms.
  • examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl.
  • the ring may be saturated or have one or more double bonds (i.e. partially unsaturated), but not fully conjugated, and not aryl, as defined herein.
  • halo includes fluoro, chloro, bromo, and iodo
  • halogen includes fluorine, chlorine, bromine, and iodine
  • heteroaryl refers to aryl
  • 8- to 12-membered bicyclic rings containing one or more, for example, from 1 to 4, or, in some embodiments, from 1 to 3, heteroatoms selected from N, O, and S, with the remaining ring atoms being carbon and wherein at least one heteroatom is present in an aromatic ring; and
  • 11- to 14-membered tricyclic rings containing one or more, for example, from 1 to 4, or in some embodiments, from 1 to 3, heteroatoms selected from N, O, and S, with the remaining ring atoms being carbon and wherein at least one heteroatom is present in an aromatic ring.
  • heteroaryl includes a 5- to 7-membered heterocyclic aromatic ring fused to a 5- to 7-membered cycloalkyl ring.
  • bicyclic heteroaryl ring systems wherein only one of the rings contains one or more heteroatoms, the point of attachment is at the heteroaromatic ring.
  • the total number of S and O atoms in the heteroaryl group exceeds 1, those heteroatoms are not adjacent to one another. In some embodiments, the total number of S and O atoms in the heteroaryl group is not more than 2. In some embodiments, the total number of S and O atoms in the aromatic heterocycle is not more than 1.
  • heteroaryl groups include, but are not limited to, (as numbered from the linkage position assigned priority 1), 2-pyridyl, 3-pyridyl, 4-pyridyl, 2,3-pyrazinyl, 3,4-pyrazinyl, 2,4-pyrimidinyl, 3,5-pyrimidinyl, 1-pyrazolyl, 2,3-pyrazolyl, 2,4-imidazolinyl, isoxazolyl, oxazolyl, thiazolyl, thiadiazolyl, tetrazolyl, thienyl, benzothienyl, furyl, benzofuryl, benzoimidazolinyl, indolinyl, pyridizinyl, triazolyl, quinolinyl, pyrazolyl, and 5,6,7,8-tetrahydroisoquinoline.
  • Bivalent radicals derived from univalent heteroaryl radicals whose names end in “-yl” by removal of one hydrogen atom from the atom with the free valence are named by adding “-idene” to the name of the corresponding univalent radical, e.g., a pyridyl group with two points of attachment is a pyridylidene.
  • Heteroaryl does not encompass or overlap with aryl as defined above.
  • Substituted heteroaryl also includes ring systems substituted with one or more oxide (—O ⁇ ) substituents, such as pyridinyl N-oxides.
  • heterocycle is meant a 4- to 12-membered monocyclic, bicyclic or tricyclic saturated or partially unsaturated ring containing at least 2 carbon atoms in addition to 1-3 heteroatoms independently selected from oxygen, sulfur, and nitrogen. “Heterocycle” also refers to 5- to 7-membered heterocyclic ring containing one or more heteroatoms selected from N, O, and S fused with 5-, 6-, and/or 7-membered cycloalkyl, heterocyclic, carbocyclic aromatic or heteroaromatic ring, provided that the point of attachment is at the heterocyclic ring.
  • Heterocycle also refers to an aliphatic spirocyclic ring containing one or more heteroatoms selected from N, O, and S, provided that the point of attachment is at the heterocyclic ring.
  • the rings may be saturated or have one or more double bonds (i.e. partially unsaturated).
  • the heterocycle can be substituted by oxo.
  • the point of the attachment may be carbon or heteroatom in the heterocyclic ring.
  • a heterocyle is not a heteroaryl as defined herein.
  • Suitable heterocycles include, for example (as numbered from the linkage position assigned priority 1), 1-pyrrolidinyl, 2-pyrrolidinyl, 2,4-imidazolidinyl, 2,3-pyrazolidinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, and 2,5 Morpholinyl groups are also contemplated, including 2-morpholinyl and 3-morpholinyl (numbered wherein the oxygen is assigned priority 1).
  • Substituted heterocycle also includes ring systems substituted with one or more oxo moieties, such as piperidinyl N-oxide, morpholinyl-N-oxide, 1-oxo-1-thiomorpholinyl and 1,1
  • optionally substituted alkyl encompasses both “unsubstituted alkyl” and “substituted alkyl” as defined below. It will be understood by those skilled in the art, with respect to any group containing one or more substituents, that such groups are not intended to introduce any substitution or substitution patterns that are sterically impractical, synthetically non-feasible and/or inherently unstable.
  • substituted means that any one or more hydrogens on the designated atom or group is replaced with a selection from the indicated group, provided that the designated atom's normal valence is not exceeded.
  • a substituent is oxo (i.e., ⁇ O) then 2 hydrogens on the atom are replaced.
  • Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds or useful synthetic intermediates.
  • a stable compound or stable structure is meant to imply a compound that is sufficiently robust to survive isolation from a reaction mixture, and subsequent formulation as an agent having at least practical utility.
  • substituents are named into the core structure. For example, it is to be understood that when (cycloalkyl)alkyl is listed as a possible substituent, the point of attachment of this substituent to the core structure is in the alkyl portion.
  • substituted with one or more groups refers to two hydrogens on the designated atom or group being independently replaced with two selections from the indicated group of substituents. In some embodiments, “substituted with one or more groups” refers to three hydrogens on the designated atom or group being independently replaced with three selections from the indicated group of substituents. In some embodiments, “substituted with one or more groups” refers to four hydrogens on the designated atom or group being independently replaced with four selections from the indicated group of substituents.
  • Compounds described herein include, but are not limited to, when possible, to the extent that they can be made by one of ordinary skill without undue experimentation, their regioisomers, their N-oxide derivatives, their optical isomers, such as enantiomers and diastereomers, mixtures of enantiomers, including racemates, mixtures of diastereomers, and other mixtures thereof, to the extent they can be made by one of ordinary skill in the art by routine experimentation.
  • the single enantiomers or diastereomers i.e., optically active forms, can be obtained by asymmetric synthesis or by resolution of the racemates or mixtures of enantiomers or diastereomers.
  • Racemates or mixtures of diastereomers can be accomplished, for example, by conventional methods such as crystallization in the presence of a resolving agent, or chromatography, using, for example a chiral high-pressure liquid chromatography (HPLC) column.
  • HPLC high-pressure liquid chromatography
  • such compounds include Z- and E-forms (or cis- and trans-forms) of compounds with carbon-carbon double bonds.
  • Such compounds also include crystal forms including polymorphs and clathrates, to the extent they can be made by one of ordinary skill in the art without undue experimentation.
  • the term “salt” is intended to include all isomers, racemates, other mixtures, Z- and E-forms, tautomeric forms and crystal forms of the salt of the compound, to the extent they can be made by one of ordinary skill in the art without undue experimentation.
  • “Pharmaceutically acceptable salts” include, but are not limited to salts with inorganic acids, such as hydrochlorate, phosphate, diphosphate, hydrobromate, sulfate, sulfinate, nitrate, and like salts; as well as salts with an organic acid, such as malate, maleate, fumarate, tartrate, succinate, citrate, acetate, lactate, methanesulfonate, p-toluenesulfonate, 2-hydroxyethylsulfonate, benzoate, salicylate, stearate, and alkanoate such as acetate, salts with HOOC—(CH 2 ) n —COOH where n is 0-4, and like salts.
  • pharmaceutically acceptable cations include, but are not limited to sodium, potassium, calcium, aluminum, lithium, and ammonium.
  • the free base can be obtained by basifying a solution of the acid salt.
  • an addition salt particularly a pharmaceutically acceptable addition salt, may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds.
  • a “solvate,” such as a “hydrate,” is formed by the interaction of a solvent and a compound.
  • the term “compound” is intended to include solvates, including hydrates, of compounds, to the extent they can be made by one of ordinary skill in the art by routine experimentation.
  • “salts” includes solvates, such as hydrates, of salts, to the extent they can be made by one of ordinary skill in the art by routine experimentation.
  • Suitable solvates are pharmaceutically acceptable solvates, such as hydrates, including monohydrates and hemi-hydrates, to the extent they can be made by one of ordinary skill in the art by routine experimentation.
  • a “chelate” is formed by the coordination of a compound to a metal ion at two (or more) points.
  • the term “compound” is intended to include chelates of compounds to the extent they can be made by one of ordinary skill in the art by routine experimentation. Similarly, “salts” includes chelates of salts.
  • non-covalent complex is formed by the interaction of a compound and another molecule wherein a covalent bond is not formed between the compound and the molecule.
  • complexation can occur through van der Waals interactions, hydrogen bonding, and electrostatic interactions (also called ionic bonding).
  • Such non-covalent complexes are included in the term “compound” to the extent they can be made by one of ordinary skill in the art by routine experimentation.
  • hydrogen bond refers to a form of association between an electronegative atom (also known as a hydrogen bond acceptor) and a hydrogen atom attached to a second, relatively electronegative atom (also known as a hydrogen bond donor).
  • Suitable hydrogen bond donor and acceptors are well understood in medicinal chemistry (G. C. Pimentel and A. L. McClellan, The Hydrogen Bond, Freeman, San Francisco, 1960; R. Taylor and O. Kennard, “Hydrogen Bond Geometry in Organic Crystals”, Accounts of Chemical Research, 17, pp. 320-326 (1984)).
  • group As used herein the terms “group”, “radical” or “fragment” are synonymous and are intended to indicate functional groups or fragments of molecules attachable to a bond or other fragments of molecules.
  • Treating,” “treat,” or “treatment” or “alleviation” refers to administering at least one compound and/or at least one pharmaceutically acceptable salt thereof described herein to a subject that has a disease or disorder, or has a symptom of a disease or disorder, or has a predisposition toward a disease or disorder, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve, or affect cancer, the symptoms of the disease or disorder, or the predisposition toward the disease or disorder.
  • the disease or disorder may be cancer.
  • the disease or disorder may be an inflammatory disease.
  • an effective amount refers to an amount of at least one compound and/or at least one pharmaceutically acceptable salt thereof described herein effective to “treat”, as defined above, a disease or disorder in a subject responsive to the inhibition of Syk.
  • the effective amount may cause any of the changes observable or measurable in a subject as described in the definition of “treating,” “treat,” “treatment” and “alleviation” above.
  • the effective amount can reduce the number of cancer or tumor cells; reduce the tumor size; inhibit or stop tumor cell infiltration into peripheral organs including, for example, the spread of tumor into soft tissue and bone; inhibit and stop tumor metastasis; inhibit and stop tumor growth; relieve to some extent one or more of the symptoms associated with the cancer, reduce morbidity and mortality; improve quality of life; or a combination of such effects.
  • An effective amount may be an amount sufficient to decrease the symptoms of a disease responsive to inhibition of Syk kinase
  • an effective amount may also refer to an amount of at least one compound and/or at least one pharmaceutically acceptable salt described herein effective to inhibit the activity of Syk in a subject responsive to the inhibition of Syk.
  • inhibitors indicates a decrease in the baseline activity of a biological activity or process.
  • “Inhibition of Syk” refers to a decrease in the activity of Syk kinase as a direct or indirect response to the presence of at least one compound and/or at least one pharmaceutically acceptable salt thereof described herein, relative to the activity of Syk kinase in the absence of the at least one compound and/or the at least one pharmaceutically acceptable salt thereof.
  • R 1 is independently chosen from hydrogen, halo, —CN, hydroxyl, optionally substituted C 1 -C 6 alkyl, optionally substituted C 3 -C 6 cycloalkyl, optionally substituted amino, and optionally substituted C 1 -C 6 alkoxy,
  • R 2 is —NR 5 R 6 , —OR 7 , —S(O) n R 8 , —C(O)R 9 , —C(O)OR 7 , —C(O)NR 5 R 6 , —NR 5 C(O)R 9 , —NR 5 S(O) n R 8 , —NR 5 S(O) n NR 10 R 11 , —NR 5 C(O)OR 7 , —NR 5 C(O)NR 10 R 11 , —S(O) n NR 5 R 6 , optionally substituted lower alkyl, optionally substituted alkenyl, and optionally substituted alkynyl;
  • R 3 and R 4 are independently selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, —NR 5 R 6 , —OR 7 , —S(O) n R 8 , —C(O)R 9 , —C(O)OR 7 , —CN, —C(O)NR 5 R 6 , —NR 5 C(O)R 9 , —NR 5 S(O) n R 8 , —NR 5 S(O) n NR 10 R 11 , —NR 5 C(O)OR 7 , —NR 5 C(O)NR 10 R 11 , —NO 2 , —S(O) n NR 5 R 6 , optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted heteroaryl, optionally substituted aryl, optionally
  • R 3 and R 4 together with the N atom to which they are attached, can form a 4-12 membered mono-cyclic, fused bicyclic or spirocyclic ring optionally containing an additional 1-3 hetero-atoms chosen from N, O and S, which is optionally substituted with one or more groups selected from halo, —NR 5 R 6 , —OR 7 , —S(O) n R 8 , —C(O)R 9 , —C(O)OR 7 , —CN, —C(O)NR 5 R 6 , —NR 5 C(O)R 9 , —NR 5 S(O) n R 8 , —NR 5 S(O) n NR 10 R 11 , —NR 5 C(O)OR 7 , —NR 5 C(O)NR 10 R 11 , —NO 2 , —S(O) n NR 5 R 6 , optionally substituted lower alkyl, optionally substituted cycloalky
  • n 0, 1 or 2
  • n 1 or 2
  • R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are independently selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, hydroxyl, cyano, optionally substituted lower alkyl, optionally substituted lower alkoxyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylacyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted amino, and optionally substituted amide, optionally substituted sulfonamide,
  • R 5 and R 6 , R 5 and R 7 , R 5 and R 8 , R 5 and R 9 , and R 5 and R 10 together with the atom(s) to which they are attached can form a ring, which is optionally substituted with one or more groups selected from halo, hydroxyl, cyano, optionally substituted lower alkyl, optionally substituted lower alkoxyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylacyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted amino, and optionally substituted amide, optionally substituted sulfonamide.
  • each optionally substituted group above for which the substituent(s) is (are) not specifically designated can be unsubstituted or independently substituted with, for example, one or more, such as one, two, or three, substituents independently chosen from C 1 -C 4 alkyl, cycloalkyl, aryl, heterocycle, heteroaryl, aryl-C 1 -C 4 alkyl-, heteroaryl-C 1 -C 4 alkyl-, C 1 -C 4 haloalkyl-, —OC 1 -C 4 alkyl, —OC 1 -C 4 alkylphenyl, —C 1 -C 4 alkyl-OH, —C 1 -C 4 alkyl-O—C 1 -C 4 alkyl, —OC 1 -C 4 haloalkyl, halo, —OH, —NH 2 , —C 1 -C 4 alkyl-NH 2 , —N(C 1 -C 4 alkyl,
  • R 1 is independently chosen from hydrogen, halo, hydroxyl, —CN, optionally substituted C 1 -C 6 alkyl, optionally substituted C 3 -C 6 cycloalkyl, optionally substituted amino, and optionally substituted C 1 -C 6 alkoxy.
  • R 1 is independently chosen from hydrogen, halo, —CN, hydroxyl; or is chosen from methyl, ethyl, n-propyl, i-propyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, N-methylamino, N-ethylamino, N-n-propylamino, N-i-propylamino, methoxy, ethoxy, propoxy, isopropoxy, each of which is optionally substituted.
  • R 1 is independently chosen from hydrogen, hydroxyl, and alkyl.
  • m is 1.
  • R 2 is C 5 -C 10 aryl, 3-8 membered heterocycle, or 5-10 membered heteroaryl, which is optionally substituted by one or more groups selected from halo, —NR 5 R 6 , —OR 7 , —S(O) n R 8 , —C(O)R 9 , —C(O)OR 7 , —CN, —C(O)NR 5 R 6 , —NR 5 C(O)R 9 , —NR 5 S(O) n R 8 , —NR 5 S(O) n NR 10 R 11 , —NR 5 C(O)OR 7 , —NR 5 C(O)NR 10 R 11 , —NO 2 , —S(O) n NR 5 R 6 , optionally substituted C 1 -C 6 alkyl, optionally substituted C 3 -C 8 cycloalkyl, optionally substituted 3-8 membered heterocycle, optionally substituted 5-10 member
  • R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are independently selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, hydroxyl, cyano, optionally substituted lower alkyl, optionally substituted lower alkoxyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylacyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted amino, and optionally substituted amide, optionally substituted sulfonamide,
  • R 5 and R 6 , R 5 and R 7 , R 5 and R 8 , R 5 and R 9 , and R 5 and R 10 together with the atom(s) to which they are attached can form a ring, which is optionally substituted with one or more groups selected from halo, hydroxyl, cyano, optionally substituted lower alkyl, optionally substituted lower alkoxyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylacyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted amino, and optionally substituted amide, optionally substituted sulfonamide.
  • R 2 is independently chosen from phenyl, naphthyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrazolyl, imidazolinyl, oxazolyl, isoxazolyl, thiazolyl, thienyl, furyl, benzofuryl, benzothienyl, benzoimidazolinyl, indolyl, quinolinyl, pyrrolidinyl, tetrahydrofuryl, piperidinyl, piperazinyl, morpholinyl, homomorpholinyl, thiomorpholinyl, diazepanyl, oxazepanyl, which is optionally substituted by one or more groups selected from halo, —NR 5 R 6 , —OR 7 , —S(O) n R 8 , —C(O)R 9 , —C(O)OR
  • R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are independently selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, hydroxyl, cyano, optionally substituted lower alkyl, optionally substituted lower alkoxyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylacyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted amino, and optionally substituted amide, optionally substituted sulfonamide,
  • R 5 and R 6 , R 5 and R 7 , R 5 and R 8 , R 5 and R 9 , and R 5 and R 10 together with the atom(s) to which they are attached can form a ring, which is optionally substituted with one or more groups selected from halo, hydroxyl, cyano, optionally substituted lower alkyl, optionally substituted lower alkoxyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylacyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted amino, and optionally substituted amide, optionally substituted sulfonamide.
  • R 2 is chosen from
  • R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are independently selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, hydroxyl, cyano, optionally substituted lower alkyl, optionally substituted lower alkoxyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylacyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted amino, and optionally substituted amide, optionally substituted sulfonamide,
  • R 5 and R 6 , R 5 and R 7 , R 5 and R 8 , R 5 and R 9 , and R 5 and R 10 together with the atom(s) to which they are attached can form a ring, which is optionally substituted with one or more groups selected from halo, hydroxyl, cyano, optionally substituted lower alkyl, optionally substituted lower alkoxyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylacyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted amino, and optionally substituted amide, optionally substituted sulfonamide.
  • R 2 is chosen from
  • R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are independently selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, hydroxyl, cyano, optionally substituted lower alkyl, optionally substituted lower alkoxyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylacyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted amino, and optionally substituted amide, optionally substituted sulfonamide,
  • R 5 and R 6 , R 5 and R 7 , R 5 and R 8 , R 5 and R 9 , and R 5 and R 10 together with the atom(s) to which they are attached can form a ring, which is optionally substituted with one or more groups selected from halo, hydroxyl, cyano, optionally substituted lower alkyl, optionally substituted lower alkoxyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylacyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted amino, and optionally substituted amide, optionally substituted sulfonamide.
  • R 2 is
  • R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are independently selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, hydroxyl, cyano, optionally substituted lower alkyl, optionally substituted lower alkoxyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylacyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted amino, and optionally substituted amide, optionally substituted sulfonamide,
  • R 5 and R 6 , R 5 and R 7 , R 5 and R 8 , R 5 and R 9 , and R 5 and R 10 together with the atom(s) to which they are attached can form a ring, which is optionally substituted with one or more groups selected from halo, hydroxyl, cyano, optionally substituted lower alkyl, optionally substituted lower alkoxyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylacyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted amino, and optionally substituted amide, optionally substituted sulfonamide.
  • R 2 is
  • R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are independently selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, hydroxyl, cyano, optionally substituted lower alkyl, optionally substituted lower alkoxyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylacyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted amino, and optionally substituted amide, optionally substituted sulfonamide,
  • R 5 and R 6 , R 5 and R 7 , R 5 and R 8 , R 5 and R 9 , and R 5 and R 10 together with the atom(s) to which they are attached can form a ring, which is optionally substituted with one or more groups selected from halo, hydroxyl, cyano, optionally substituted lower alkyl, optionally substituted lower alkoxyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylacyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted amino, and optionally substituted amide, optionally substituted sulfonamide.
  • R 3 and R 4 are independently selected from hydrogen, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 5 -C 10 aryl, 5-10 membered heteroaryl, and 3-8 membered heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, —NR 5 R 6 , —OR 7 , —S(O) n R 8 , —C(O)R 9 , —C(O)OR′, —CN, —C(O)NR 5 R 6 , —NR 5 C(O)R 9 , —NR 5 S(O) n R 8 , —NR 5 S(O) n NR 10 R 11 , —NR 5 C(O)OR 7 , —NR 5 C(O)NR 10 R 11 , —NO 2 , —S(O) n NR 5 R 6 , optionally substituted C 1 -C 6 alkyl,
  • R 3 and R 4 together with the N atom to which they are attached, can form a 4-12 membered mono-cyclic, fused bicyclic or spirocyclic ring optionally containing an additional 1-3 hetero-atoms chosen from N, O and S, which is optionally substituted with one or more groups selected from halo, —NR 5 R 6 , —OR 7 , —S(O) n R 8 , —C(O)R 9 , —C(O)OR 7 , —CN, —C(O)NR 5 R 6 , —NR 5 C(O)R 9 , —NR 5 S(O) n R 8 , —NR 5 S(O) n NR 10 R 11 , —NR 5 C(O)OR 7 , —NR 5 C(O)NR 10 R 11 , —NO 2 , —S(O) n NR 5 R 6 , optionally substituted C 1 -C 6 alkyl, optionally substituted
  • R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are independently selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, hydroxyl, cyano, optionally substituted lower alkyl, optionally substituted lower alkoxyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylacyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted amino, and optionally substituted amide, optionally substituted sulfonamide,
  • R 5 and R 6 , R 5 and R 7 , R 5 and R 8 , R 5 and R 9 , and R 5 and R 10 together with the atom(s) to which they are attached can form a ring, which is optionally substituted with one or more groups selected from halo, hydroxyl, cyano, optionally substituted lower alkyl, optionally substituted lower alkoxyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylacyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted amino, and optionally substituted amide, optionally substituted sulfonamide.
  • R 3 and R 4 are independently selected from hydrogen, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, and t-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, phenyl, naphthyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrazolyl, imidazolinyl, oxazolyl, isoxazolyl, thiazolyl, thienyl, furyl, benzofuryl, benzothienyl, benzoimidazolinyl, indolyl, quinolinyl, and pyrrolidinyl, tetrahydrofuryl, piperidinyl, piperazinyl,
  • R 3 and R 4 together with the N atom to which they are attached, can form a 4-12 membered mono-cyclic, fused bicyclic or spirocyclic ring optionally containing an additional 1-3 hetero-atoms chosen from N, O and S, which is optionally substituted with one or more groups selected from halo, —NR 5 R 6 , —OR 7 , —S(O) n R 8 , —C(O)R 9 , —C(O)OR 7 , —CN, —C(O)NR 5 R 6 , —NR 5 C(O)R 9 , —NR 5 S(O) n R 8 , —NR 5 S(O) n NR 10 R 11 , —NR 5 C(O)OR 7 , —NR 5 C(O)NR 10 R 11 , —NO 2 , —S(O) n NR 5 R 6 ; or selected from methyl, ethyl, n-propyl
  • R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are independently selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, hydroxyl, cyano, optionally substituted lower alkyl, optionally substituted lower alkoxyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylacyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted amino, and optionally substituted amide, optionally substituted sulfonamide,
  • R 5 and R 6 , R 5 and R 7 , R 5 and R 8 , R 5 and R 9 , and R 5 and R 10 together with the atom(s) to which they are attached can form a ring, which is optionally substituted with one or more groups selected from halo, hydroxyl, cyano, optionally substituted lower alkyl, optionally substituted lower alkoxyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylacyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted amino, and optionally substituted amide, optionally substituted sulfonamide.
  • R 4 is H and R 3 is lower alkyl, which is optionally substituted with one or more groups selected from alkyl, cycloalkyl, heterocycle and heteroaryl, each of which is optionally substituted by one or more groups chosen from halo, —NR 5 R 6 , —OR 7 , —S(O) n R 8 , —C(O)R 9 , —C(O)OR 7 , —CN, —C(O)NR 5 R 6 , —NR 5 C(O)R 9 , —NR 5 S(O) n R 8 , —NR 5 S(O) n NR 10 R 11 , —NR 5 C(O)OR 7 , —NR 5 C(O)NR 10 R 11 , —NO 2 , —S(O) n NR 5 R 6 , optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted heteroaryl,
  • R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are independently selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, hydroxyl, cyano, optionally substituted lower alkyl, optionally substituted lower alkoxyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylacyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted amino, and optionally substituted amide, optionally substituted sulfonamide,
  • R 5 and R 6 , R 5 and R 7 , R 5 and R 8 , R 5 and R 9 , and R 5 and R 10 together with the atom(s) to which they are attached can form a ring, which is optionally substituted with one or more groups selected from halo, hydroxyl, cyano, optionally substituted lower alkyl, optionally substituted lower alkoxyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylacyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted amino, and optionally substituted amide, optionally substituted sulfonamide.
  • R 3 and R 4 together with the N atom to which they are attached can form a 4-12 membered mono-cyclic ring optionally containing an additional 1-3 hetero-atoms chosen from N, O and N, which is optionally substituted with one or more groups selected from halo, —NR 5 R 6 , —OR 7 , —S(O) n R 8 , —C(O)R 9 , —C(O)OR′, —CN, —C(O)NR 5 R 6 , —NR 5 C(O)R 9 , —NR 5 S(O) n R 8 , —NR 5 S(O) n NR 10 R 11 , —NR 5 C(O)OR 7 , —NR 5 C(O)NR 10 R 11 , —NO 2 , —S(O) n NR 5 R 6 , optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally
  • R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are independently selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, hydroxyl, cyano, optionally substituted lower alkyl, optionally substituted lower alkoxyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylacyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted amino, and optionally substituted amide, optionally substituted sulfonamide,
  • R 5 and R 6 , R 5 and R 7 , R 5 and R 8 , R 5 and R 9 , and R 5 and R 10 together with the atom(s) to which they are attached can form a ring, which is optionally substituted with one or more groups selected from halo, hydroxyl, cyano, optionally substituted lower alkyl, optionally substituted lower alkoxyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylacyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted amino, and optionally substituted amide, optionally substituted sulfonamide.
  • R 3 and R 4 together with the N atom to which they are attached can form a 7-14 membered fused bicyclic ring optionally containing an additional 1-3 hetero-atoms chosen from N, O and N, which is optionally substituted with one or more groups selected from halo, —NR 5 R 6 , —OR 7 , —S(O) n R 8 , —C(O)R 9 , —C(O)OR 7 , —CN, —C(O)NR 5 R 6 , —NR 5 C(O)R 9 , —NR 5 S(O) n R 8 , —NR 5 S(O) n NR 10 R 11 , —NR 5 C(O)OR 7 , —NR 5 C(O)NR 10 R 11 , —NO 2 , —S(O) n NR 5 R 6 , optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted heterocycle,
  • R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are independently selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, hydroxyl, cyano, optionally substituted lower alkyl, optionally substituted lower alkoxyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylacyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted amino, and optionally substituted amide, optionally substituted sulfonamide,
  • R 5 and R 6 , R 5 and R 7 , R 5 and R 8 , R 5 and R 9 , and R 5 and R 10 together with the atom(s) to which they are attached can form a ring, which is optionally substituted with one or more groups selected from halo, hydroxyl, cyano, optionally substituted lower alkyl, optionally substituted lower alkoxyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylacyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted amino, and optionally substituted amide, optionally substituted sulfonamide.
  • R 3 and R 4 together with the N atom to which they are attached can form a 7-14 membered spirocyclic ring optionally containing an additional 1-3 hetero-atoms chosen from N, O and N, which is optionally substituted with one or more groups selected from halo, —NR 5 R 6 , —OR 7 , —S(O) n R 8 , —C(O)R 9 , —C(O)OR′, —CN, —C(O)NR 5 R 6 , —NR 5 C(O)R 9 , —NR 5 S(O) n R 8 , —NR 5 S(O) n NR 10 R 11 , —NR 5 C(O)OR 7 , —NR 5 C(O)NR 10 R 11 , —NO 2 , —S(O) n NR 5 R 6 , optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted heterocycle,
  • R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are independently selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, hydroxyl, cyano, optionally substituted lower alkyl, optionally substituted lower alkoxyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylacyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted amino, and optionally substituted amide, optionally substituted sulfonamide,
  • R 5 and R 6 , R 5 and R 7 , R 5 and R 8 , R 5 and R 9 , and R 5 and R 10 together with the atom(s) to which they are attached can form a ring, which is optionally substituted with one or more groups selected from halo, hydroxyl, cyano, optionally substituted lower alkyl, optionally substituted lower alkoxyl, optionally substituted lower alkylsulfonyl, optionally substituted lower alkylacyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted amino, and optionally substituted amide, optionally substituted sulfonamide.
  • the optionally substituted lower alkyl is chosen from CF 3 , CF 2 H, aminoalkyl, hydroxyalkyl, alkoxyalkyl, and haloalkyl.
  • At least one compound chosen from compounds 1 to 516 and/or at least one pharmaceutically acceptable salt thereof is provided.
  • compounds of formula (1) can react with compounds of formula (2), wherein n, R 1 , R 2 and R 3 are as defined herein, X 1 and X 2 are halo chosen from Cl, Br or I, in the presence of a base, such as but not limited to K 2 CO 3 , Na 2 CO 3 , NaH, Et 3 N or diisopropylethylamine (DIPEA), to give compounds of formula (3) that can react with compounds of formula (4), wherein R 2 is as defined herein, M is chosen from boronic acid/ester or a tin substituted with C 1 -C 4 alkyl groups, under the catalysis of a palladium reagent, such as but not limited to PdCl 2 , Pd(OAc) 2 Pd 2 (dba) 3 or Pd(PPh 3 ) 4 , and a ligand, such as but not limited to Ph 3 P, t Bu 3 P, 2,2′-bis(diphenylphos
  • the compounds thus obtained can be further modified at their peripheral positions to provide the desired compounds.
  • Synthetic chemistry transformations are described, for example, in R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989); T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 3 rd Ed., John Wiley and Sons (1999); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis , John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis , John Wiley and Sons (1995) and subsequent editions thereof.
  • the at least one compound and/or at least one pharmaceutically acceptable salt described herein can be purified by column chromatography, high performance liquid chromatography, crystallization, or other suitable methods.
  • a composition comprising at least one compound and/or at least one pharmaceutically acceptable salt described herein can be administered in various known manners, such as orally, parenterally, by inhalation spray, or via an implanted reservoir.
  • parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.
  • a sterile injectable composition e.g., aqueous or oleaginous suspension
  • a sterile injectable composition can be formulated according to techniques known in the art using suitable dispersing or wetting agents (such as, for example, Tween 80) and suspending agents.
  • the sterile injectable Intermediate can also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
  • suitable dispersing or wetting agents such as, for example, Tween 80
  • the sterile injectable Intermediate can also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
  • the pharmaceutically acceptable vehicles and solvents that can be employed are mannitol, water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium (e.g., synthetic mono- or di-glycerides).
  • Fatty acids such as oleic acid and its glyceride derivatives are useful in the Intermediate of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
  • These oil solutions or suspensions can also contain a long-chain alcohol diluent or dispersant, or carboxymethyl cellulose or similar dispersing agents.
  • An inhalation composition can be prepared according to techniques well known in the art of pharmaceutical formulation and can be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art.
  • Creams may be formulated from a mixture of mineral oil, self-emulsifying beeswax and water in which mixture the active ingredient, dissolved in a small amount of an oil, such as almond oil, is admixed.
  • An example of such a cream is one which includes about 40 parts water, about 20 parts beeswax, about 40 parts mineral oil and about 1 part almond oil.
  • Ointments may be formulated by mixing a solution of the active ingredient in a vegetable oil, such as almond oil, with warm soft paraffin and allowing the mixture to cool.
  • An example of such an ointment is one which includes about 30% by weight almond oil and about 70% by weight white soft paraffin.
  • the method comprises contacting the at least one kinase with an amount of at least one compound and/or at least one pharmaceutically acceptable salt described herein effective to inhibit the activity of the Syk kinase.
  • the at least one compound and/or at least one pharmaceutically acceptable salt described herein can be used to achieve a beneficial therapeutic or prophylactic effect, for example, in subjects with an inflammatory disease or inflammatory disorder.
  • inflammatory disease or “inflammatory disorder” refers to pathological states resulting in inflammation, typically caused by neutrophil chemotaxis.
  • disorders include inflammatory skin diseases including psoriasis and atopic dermatitis; systemic scleroderma and sclerosis; responses associated with inflammatory bowel disease (IBD) (such as Crohn's disease and ulcerative colitis); ischemic reperfusion disorders including surgical tissue reperfusion injury, myocardial ischemic conditions such as myocardial infarction, cardiac arrest, reperfusion after cardiac surgery and constriction after percutaneous transluminal coronary angioplasty, stroke, and abdominal aortic aneurysms; cerebral edema secondary to stroke; cranial trauma, hypovolemic shock; asphyxia; adult respiratory distress syndrome; acute-lung injury; Behcet's Disease; dermatomyositis; polymyositis; multiple sclerosis (MS); dermatitis; meningitis; encephalitis; uveitis; osteoarthritis; lupus nephritis; autoimmune diseases such as rheumatoid arthritis
  • the preferred indications include, without limitation, chronic inflammation, autoimmune diabetes, rheumatoid arthritis (RA), rheumatoid spondylitis, gouty arthritis and other arthritic conditions, multiple sclerosis (MS), asthma, systhemic lupus erythrematosus, adult respiratory distress syndrome, Behcet's disease, psoriasis, chronic pulmonary inflammatory disease, graft versus host reaction, Crohn's Disease, ulcerative colitis, inflammatory bowel disease (IBD), Alzheimer's disease, and pyresis, along with any disease or disorder that relates to inflammation and related disorders.
  • the at least one compound and/or at least one pharmaceutically acceptable salt described herein is administered in conjunction with an anti-inflammatory agent.
  • anti-inflammatory agents include corticosteroids (e.g., fluticasone propionate, beclomethasone dipropionate, mometasone furoate, triamcinolone acetonide or budesonide), disease-modifying agents (e.g., antimalarials, methotrexate, sulfasalazine, mesalamine, azathioprine, 6 metronidazole, injectable and oral gold, or D-penicillamine), non-steroidal antiinflammatory drugs (e.g., acetominophen, aspirin, sodium salicylate, sodium cromoglycate, magnesium salicylate, choline magnesium salicylate, salicylsalicylic acid, ibuprofen, naproxen, diclofenac, diflunisal, etodolac,
  • corticosteroids
  • 2,6-dichloropyridine-4-ylamine (10.0 g, 61 mmol) was slowly added in concentrated sulfuric acid (64 mL) at the rate to keep the internal reaction temperature ⁇ 10° C.
  • the mixture was then cooled to ⁇ 5° C. and nitric acid (90%, 30 mL) was added dropwise to keep the reaction temperature below 0° C. over a period of 40 minutes.
  • the reaction mixture was stirred at 0° C. for 2 hours and then poured into ice-water (500 mL). The title compound was isolated by filtration and dried in vacuo for the next step.
  • N-(2,6-dichloropyridin-4-yl)nitramide from the previous step was slowly added into concentrated sulfuric acid (64 mL) at a rate sufficient to keep the internal reaction temperature ⁇ 40° C.
  • the precipitates were collected by filtration and dried in vacuo to give the title compound.
  • tert-butyl 3-(aminomethyl)-3-fluoropiperidine-1-carboxylate (3.86 g, 16.6 mmol) and DIPEA (3.22 g, 24.9 mmol) were added to a solution of 5,7-dichloropyrido[3,4-b]pyrazine (3.32 g, 16.6 mmol) in THF (60 mL) and the mixture was refluxed overnight. The volatile components were evaporated and the residue was extracted with ethyl acetate. Ethyl acetate was washed with brine and dried.
  • Tetrabutylammonium bromide (1.06 g, 3.3 mmol) is added to a solution of 1-(4-bromophenyl)piperidin-4-ol (2.56 g, 10 mmol) in toluene (30 mL). The reaction mixture was cooled to 0° C. and aq. 35% sodium hydroxide (30 mL) was added followed by a drop-wise addition of tert-butyl bromoacetate (2.92 g, 15 mmol). The mixture was then allowed to reach room temperature and was stirred for 17 hours at this temperature.
  • tert-Butyl 3,3-difluoro-5-((7-(4-morpholinophenyl)pyrido[4,3-b]pyrazin-5-ylamino)methyl)piperidine-1-carboxylate from step A (227 mg, 0.42 mmol) was treated with HCl solution (in EtOAc, 5 N) at room temperature until the reaction was finished. The volatiles were removed under reduced pressure, dissolved in dichloromethane (5 mL), and neutralized with ammonium hydroxide.
  • 1-(4-bromophenyl)piperidin-4-ol 300 mg, 1.17 mmol
  • tetrakis(triphenylphosphine)palladium 270 mg, 0.23 mmol
  • 1,1,1,2,2,2-hexamethyldistannane 499 mg, 1.52 mmol
  • Pro-1 is (S)-3-(4-(5-(morpholin-2-ylmethylamino)pyrido[4,3-b]pyrazin-7-yl)phenoxy)propan-1-ol, MS (m/z): 396 (M+H) + .
  • Pro-2 is (S)-3-(4-(5-(morpholin-2-ylmethylamino)pyrido[4,3-b]pyrazin-7-yl)phenoxy)propyl acetate, MS (m/z): 438 (M+H) + .

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
US14/124,325 2011-06-08 2012-06-07 Substituted pyrido[3,4-b]pyrazines as Syk inhibitors Active 2032-12-22 US9434726B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CNPCT/CN2011/075431 2011-06-08
WOPCT/CN2011/075431 2011-06-08
PCT/CN2011/075431 WO2012167423A1 (en) 2011-06-08 2011-06-08 Substituted pyridopyrazines as novel syk inhibitors
PCT/CN2012/076576 WO2012167733A1 (en) 2011-06-08 2012-06-07 Substituted pyridopyrazines as novel syk inhibitors

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/CN2011/075431 Continuation-In-Part WO2012167423A1 (en) 2011-06-08 2011-06-08 Substituted pyridopyrazines as novel syk inhibitors
PCT/CN2012/076576 A-371-Of-International WO2012167733A1 (en) 2011-06-08 2012-06-07 Substituted pyridopyrazines as novel syk inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/211,353 Continuation US10052330B2 (en) 2011-06-08 2016-07-15 Substituted pyrido[3,4-b]pyrazines as Syk inhibitors

Publications (2)

Publication Number Publication Date
US20140121200A1 US20140121200A1 (en) 2014-05-01
US9434726B2 true US9434726B2 (en) 2016-09-06

Family

ID=47295336

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/124,325 Active 2032-12-22 US9434726B2 (en) 2011-06-08 2012-06-07 Substituted pyrido[3,4-b]pyrazines as Syk inhibitors
US15/211,353 Active US10052330B2 (en) 2011-06-08 2016-07-15 Substituted pyrido[3,4-b]pyrazines as Syk inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/211,353 Active US10052330B2 (en) 2011-06-08 2016-07-15 Substituted pyrido[3,4-b]pyrazines as Syk inhibitors

Country Status (31)

Country Link
US (2) US9434726B2 (ja)
EP (1) EP2718293B1 (ja)
JP (2) JP5940148B2 (ja)
KR (1) KR101571720B1 (ja)
CN (1) CN103596952B (ja)
AU (1) AU2012266941B2 (ja)
BR (1) BR112013031405B1 (ja)
CA (1) CA2836227C (ja)
CL (1) CL2013003512A1 (ja)
CY (1) CY1119953T1 (ja)
DK (1) DK2718293T3 (ja)
ES (1) ES2657549T3 (ja)
HK (1) HK1190143A1 (ja)
HR (1) HRP20180139T1 (ja)
HU (1) HUE037934T2 (ja)
IL (1) IL229410A (ja)
LT (1) LT2718293T (ja)
MX (1) MX355671B (ja)
MY (1) MY186599A (ja)
NO (1) NO2718293T3 (ja)
PE (1) PE20141167A1 (ja)
PL (1) PL2718293T3 (ja)
PT (1) PT2718293T (ja)
RS (1) RS56901B1 (ja)
RU (1) RU2569635C9 (ja)
SG (1) SG195035A1 (ja)
SI (1) SI2718293T1 (ja)
TW (1) TWI494311B (ja)
UA (1) UA111744C2 (ja)
WO (2) WO2012167423A1 (ja)
ZA (1) ZA201308947B (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11396507B2 (en) * 2017-08-22 2022-07-26 Hutchison Medipharma Limited Salts of a compound and the crystalline forms thereof

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2683716A1 (en) * 2011-03-11 2014-01-15 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
WO2012167423A1 (en) * 2011-06-08 2012-12-13 Hutchison Medipharma Limited Substituted pyridopyrazines as novel syk inhibitors
WO2014028479A1 (en) 2012-08-13 2014-02-20 Envoy Therapeutics, Inc. Quinoxaline derivatives as gpr6 modulators
WO2014086032A1 (en) * 2012-12-07 2014-06-12 Hutchison Medipharma Limited Substituted pyridopyrazines as syk inhibitors
JP6526034B2 (ja) 2014-02-14 2019-06-05 武田薬品工業株式会社 Ｇｐｒ６のピリドピラジンモジュレーター
ES2738416T3 (es) 2014-03-19 2020-01-22 Boehringer Ingelheim Int Inhibidores heteroarílicos de SYK
PE20180572A1 (es) * 2015-06-18 2018-04-04 Cephalon Inc Derivados de piperidina 1,4-sustituidos
ES2849951T3 (es) 2015-06-18 2021-08-24 89Bio Ltd Derivados de piperidina 4-bencil y 4-benzoil sustituidos
CN105153211B (zh) * 2015-09-22 2017-02-01 上海晋鲁医药科技有限公司 一种合成1‑(N‑Boc‑4‑哌啶)‑4‑吡唑硼酸频哪醇酯的方法
CN110072865B (zh) 2017-02-08 2022-02-11 中国医药研究开发中心有限公司 吡咯并芳杂环类化合物及其制备方法和医药用途
DK3655401T3 (da) * 2017-07-18 2023-10-30 Merck Patent Gmbh Tlr7/8-antagonister og anvendelser deraf
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AU2022284188A1 (en) * 2021-06-04 2023-11-30 Genentech, Inc. 2, 8-diazaspiro [4.5] decane compounds

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083485A1 (en) 2000-04-28 2001-11-08 Bayer Aktiengesellschaft Imidazopyrimidine derivatives and triazolopyrimidine derivatives
WO2003057695A1 (en) 2001-12-21 2003-07-17 Boehringer Ingelheim Pharmaceuticals, Inc. 1,6 naphthyridines useful as inhibitors of syk kinase
WO2003063794A2 (en) 2002-02-01 2003-08-07 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
WO2004005472A2 (en) 2002-07-02 2004-01-15 Southern Research Institute Inhibitors of ftsz and uses thereof
WO2006078846A1 (en) 2005-01-19 2006-07-27 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
WO2007124221A1 (en) 2006-04-18 2007-11-01 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders by using pyrimidinediamine compounds
WO2009099801A1 (en) 2008-02-01 2009-08-13 Irm Llc Pyrido [4, 3-d] pyrimidinone derivatives as kinase inhibitors
WO2011014795A2 (en) 2009-07-30 2011-02-03 Irm Llc Compounds and compositions as syk kinase inhibitors
WO2011092128A1 (en) 2010-01-29 2011-08-04 Boehringer Ingelheim International Gmbh Substituted naphthyridines and their use as syk kinase inhibitors
US20110201608A1 (en) 2008-08-05 2011-08-18 Boehringer Ingelheim International Gmbh Substituted naphthyridines and use thereof as medicines
WO2011134971A1 (en) 2010-04-29 2011-11-03 Glaxo Group Limited 7-(1h-pyrazol-4-yl)-1,6-naphthyridine compounds as syk inhibitors
WO2012123312A1 (en) 2011-03-11 2012-09-20 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
WO2013014060A1 (en) 2011-07-26 2013-01-31 Boehringer Ingelheim International Gmbh Substituted quinolines and their use as medicaments

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022779A (en) * 1974-07-25 1977-05-10 E. R. Squibb & Sons, Inc. Amino derivatives of pyrido(3,4-b)pyrazine carboxylic acids and esters
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
DE10323345A1 (de) * 2003-05-23 2004-12-16 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
RU2515944C9 (ru) * 2005-11-11 2014-07-20 Этерна Центарис ГмбХ ПРОИЗВОДНЫЕ ПИРИДОПИРАЗИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ФИЗИОЛОГИЧЕСКИХ И/ИЛИ ПАТОФИЗИОЛОГИЧЕСКИХ СОСТОЯНИЙ ПОСРЕДСТВОМ ИНГИБИРОВАНИЯ ФЕРМЕНТОВ ERK, ERK1, ERK2, PI3K, PI3Kальфа, PI3Kбета, PI3Kгамма, PI3Kдельта, PI3K-С2альфа, PI3K-С2бета, PI3K-Vps34р (ВАРИАНТЫ)
ES2661850T3 (es) * 2009-09-14 2018-04-04 Gilead Sciences, Inc. Moduladores de receptores del tipo toll
WO2012167423A1 (en) * 2011-06-08 2012-12-13 Hutchison Medipharma Limited Substituted pyridopyrazines as novel syk inhibitors

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083485A1 (en) 2000-04-28 2001-11-08 Bayer Aktiengesellschaft Imidazopyrimidine derivatives and triazolopyrimidine derivatives
WO2003057695A1 (en) 2001-12-21 2003-07-17 Boehringer Ingelheim Pharmaceuticals, Inc. 1,6 naphthyridines useful as inhibitors of syk kinase
WO2003063794A2 (en) 2002-02-01 2003-08-07 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
WO2004005472A2 (en) 2002-07-02 2004-01-15 Southern Research Institute Inhibitors of ftsz and uses thereof
WO2006078846A1 (en) 2005-01-19 2006-07-27 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
WO2007124221A1 (en) 2006-04-18 2007-11-01 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders by using pyrimidinediamine compounds
WO2009099801A1 (en) 2008-02-01 2009-08-13 Irm Llc Pyrido [4, 3-d] pyrimidinone derivatives as kinase inhibitors
US20110201608A1 (en) 2008-08-05 2011-08-18 Boehringer Ingelheim International Gmbh Substituted naphthyridines and use thereof as medicines
WO2011014795A2 (en) 2009-07-30 2011-02-03 Irm Llc Compounds and compositions as syk kinase inhibitors
WO2011092128A1 (en) 2010-01-29 2011-08-04 Boehringer Ingelheim International Gmbh Substituted naphthyridines and their use as syk kinase inhibitors
WO2011134971A1 (en) 2010-04-29 2011-11-03 Glaxo Group Limited 7-(1h-pyrazol-4-yl)-1,6-naphthyridine compounds as syk inhibitors
WO2012123312A1 (en) 2011-03-11 2012-09-20 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
WO2013014060A1 (en) 2011-07-26 2013-01-31 Boehringer Ingelheim International Gmbh Substituted quinolines and their use as medicaments

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
Braselmann, S et al., R406, an Orally Available Spleen Tyrosine Kinase Inhibitor Blocks Fc Receptor Signaling and Reduces Immune Complex-Mediated Inflammation, 2006, J. Pharmacol. and Experimental Therapeutics, 319 (3):998-1008.
Chen, D et al., Computational selection of inhibitors of Abeta aggregation and neuronal toxicity, 2009, Bioorganic & Medicinal Chemistry 17:5189-5197.
Coffey, G et al., Specific Inhibition of Spleen Tyrosine Kinase Suppresses Leukocyte Immune Function and Inflammation in Animal Models of Rheumatoid Arthritis, 2012, J Pharmacol Experiment Therapeutics, 340:350-359.
Efremov, Dimitar & Laurenti, Luca, The Syk kinase as a therapeutic target in leukemia and lymphoma, Expert Opin. Investig. Drugs 2011, 20(5): 623-636, Informa UK, Ltd.
Elliott, et al., The Isomeric Pyridopyrazines from the Reaction of Some Tetraaminopyridines with Pyruvaldehyde and Benzil, 1968, J Org Chem 33(6):2393-2397.
Elliott, R et al., Potential Folic Acid Antagonists. VI. The Syntheses of 1- and 3-Deazamethotrexate, 1971, J. Org. Chem. 36(10):2818-2823.
Friedberg, Jonathan et al, Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia, Blood, Apr. 2010, 115(13): 2578-2585.
Hackam, et al. JAMA, 296(14), 2006, 1731-1732. *
Hoffmann, C et al., Comparative Effects of Selected Antifolates on Transforming Human Lymphocytes and on Established Human Lymphoblastic Cell Lines, 1976, Biochemical Pharmacology 25:1947-1954.
Jordan, V. C. Nature Reviews: Drug Discovery, 2, 2003, 205. *
Nisius, B et al., Development of a Fingerprint Reduction Approach for Bayesian Similarity Searching Based on Kullback-Leibler Divergence Analysis, 2009, J. Chem. Inf. Model. 49:1347-1358.
Pamuk, Omer N. et al, Spleen tyrosine kinase inhibition in the treatment of autoimmune, allergic and autoinflammatory diseases, Arthritis Research & Therapy, 2010, 12(222): 1-11, BioMed Central.
Spurgeon, S et al., The Selective Syk Inhibitor P505-15 (PRT062607) Inhibits B Cell Signaling and Function In Vitro and In Vivo and Aguments the Activity of Fludarabine in Chronic Lymphocytic Leukemia, 2013, J Pharmacol Experiment Therapeutics, Feb. 2013, 344:378-387.
Temple, C et al., 1,2-Dihydropyrido[3,4-b]pyrazines: Structure-Activity Relationships, 1983, J. Med. Chem. 26:91-95.
Wheeler, G et al., Biolgoical Effects and Structure-Activity Relationships of 1,2-Dihydropyrido[3,4-b]pyrazines, Aug. 1993, Cancer Res 43:3567-3575.
Williams, J et al., The Inhibition of Dihydrofolate Reductase by Folate Analogues: Structural Requirements for Slow- and Tight-Binding Inhibition,1980, Biochemical Pharmacology, 29:589-595.
Wong, Brian R. et al., Targeting Syk as a treatment for allergic and autoimmune disorders, Expert Opin. Investig. Drugs 2004, 13(7): 743-762, Ashley Publications Ltd.
Yamamoto, N et al., The Orally Available Spleen Tyrosine Kinase Inhibitor 2-[7-(3,4-Dimethoxyphenyl)-imidao[1,2-c] pyrimidin-5-ylamino]-nicotinamide Dihydrochloride (BAY 61-3606) Blocks Antigen-Induced Airway Inflammation in Rodents, 2003, J Pharmacol Exp Ther, 306 (3): 1174-1181.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11396507B2 (en) * 2017-08-22 2022-07-26 Hutchison Medipharma Limited Salts of a compound and the crystalline forms thereof
US12084441B2 (en) 2017-08-22 2024-09-10 Hutchison Medipharma Limited Salts of a compound and the crystalline forms thereof

Also Published As

Publication number Publication date
JP6175484B2 (ja) 2017-08-02
KR101571720B1 (ko) 2015-11-25
EP2718293A1 (en) 2014-04-16
CA2836227A1 (en) 2012-12-13
RU2013158996A (ru) 2015-07-20
AU2012266941B2 (en) 2016-03-31
PE20141167A1 (es) 2014-09-03
ZA201308947B (en) 2020-02-26
NO2718293T3 (ja) 2018-03-24
TWI494311B (zh) 2015-08-01
EP2718293B1 (en) 2017-10-25
WO2012167733A1 (en) 2012-12-13
BR112013031405B1 (pt) 2021-12-21
RS56901B1 (sr) 2018-05-31
US10052330B2 (en) 2018-08-21
SG195035A1 (en) 2013-12-30
HUE037934T2 (hu) 2018-09-28
CY1119953T1 (el) 2018-12-12
TW201305160A (zh) 2013-02-01
CA2836227C (en) 2016-08-16
JP2014516059A (ja) 2014-07-07
KR20140025559A (ko) 2014-03-04
JP5940148B2 (ja) 2016-06-29
CN103596952A (zh) 2014-02-19
RU2569635C9 (ru) 2016-07-10
SI2718293T1 (en) 2018-04-30
UA111744C2 (uk) 2016-06-10
MX355671B (es) 2018-04-26
MX2013014242A (es) 2014-04-14
WO2012167423A1 (en) 2012-12-13
NZ617765A (en) 2016-02-26
DK2718293T3 (da) 2018-01-29
PL2718293T3 (pl) 2018-05-30
MY186599A (en) 2021-07-29
CN103596952B (zh) 2016-05-04
JP2016106100A (ja) 2016-06-16
US20160324864A1 (en) 2016-11-10
HRP20180139T1 (hr) 2018-05-18
ES2657549T3 (es) 2018-03-05
CL2013003512A1 (es) 2014-07-18
RU2569635C2 (ru) 2015-11-27
EP2718293A4 (en) 2014-12-03
HK1190143A1 (zh) 2014-06-27
IL229410A0 (en) 2014-01-30
PT2718293T (pt) 2018-01-30
US20140121200A1 (en) 2014-05-01
IL229410A (en) 2017-08-31
LT2718293T (lt) 2018-02-12
BR112013031405A2 (pt) 2016-12-06
AU2012266941A1 (en) 2013-11-28

Similar Documents

Publication Publication Date Title
US10052330B2 (en) Substituted pyrido[3,4-b]pyrazines as Syk inhibitors
US10369153B2 (en) Pyrrolopyrimidine compounds and uses thereof
US10766897B2 (en) Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors
EP2838898B1 (en) Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
US9914735B2 (en) Heteroaryl Syk inhibitors
US9096579B2 (en) Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments
AU2009244291B2 (en) Substituted amides, method of making, and use as Btk inhibitors
US10155751B2 (en) Pyrazolyl-substituted heteroaryls and their use as medicaments
WO2010068806A1 (en) Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer
CA2661654A1 (en) Certain substituted amides, method of making, and method of use thereof
US20150065489A1 (en) Substituted Quinolines and Their Use As Medicaments
US20150307491A1 (en) Substituted pyridopyrazines as syk inhibitors
NZ617765B2 (en) Substituted pyridopyrazines as novel syk inhibitors

Legal Events

Date Code Title Description
AS Assignment

Owner name: HUTCHISON MEDIPHARMA LIMITED, CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SU, WEI-GUO;DENG, WEI;JI, JIANGUO;SIGNING DATES FROM 20131125 TO 20131203;REEL/FRAME:031731/0228

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8